Beyond HRD tumours, this process increases the presence of tumour neoantigens, upregulates interferons and PD-L1, and alters the tumour microenvironment enhancing the immune system's ability to attack the cancer [95, 96]. The gene discussed is CD274; the disease is neoplasm.